Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Type II Diabetes Mellitus Clinical Trial

Official title:

A Randomized, Open, Comparative to the Positive-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects Newly Diagnosed as Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03059719
• Other study ID #: ICP-I-2015-01
• Status: Completed
• Phase: Phase 1
• First received: February 15, 2017
• Last updated: February 16, 2017
• Start date: April 8, 2015
• Est. completion date: October 27, 2016

Study information

• Verified date: February 2017
• Source: PegBio Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, opened, positive drug-controlled (Exenatide, Byetta), sequential parallel group, multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of twelve once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM).

Description:

There are two study phases according to different doses of investigational drug Phase 1：1 investigational group and 1 control group, i.e.; investigational drug PB-119 injection 25µg group and control drug exenatide group.

Phase 1： Plan to have 1 or 2 investigational group according to the study result from phase 1, i.e., investigational drug PB-119 injection 50 µg group and control drug exenatide group.

Subject Number：18 subjects will be randomized to each group, with equal number of females and males. 12 subjects will be in PB-119 group, 6 subjects will be in exenatide group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: October 27, 2016
• Est. primary completion date: September 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male and/or female subjects between the ages of 18~45 (inclusive) years, the ratio of females to males is approximately 1:1;

2. Subject has been disguised as type 2 diabetes within 5 years of screening, and met the diagnosis criteria of type 2 diabetes in guidance from WHO and Chinese Diabetes Society (CDS);

3. Subject didn't received any treatment for diabetes before screening, subject has been on diet control for more than 3 months, Fasting Plasma Glucose (FPG) was 7.0 ~ 13.0 mmol / L (including boundary value), and the glycosylated hemoglobin (HbA1c) was 7.0% ~ 10% (Including boundary values);

4. Female weight of =45 kg, male weight of =50 kg, subject body mass index (BMI) between 19~30 kg/m2 (inclusive);

5. Subject can understand the procedures and methods of this clinical trial, is willing to participate and sign the written informed consent;

Exclusion Criteria:

1. Subject was diagnosed as type 1 diabetes

2. Subject has acute complications of diabetes, such as ketoacidosis or hyperosmolar coma within 6 months before screening;

3. Subject who is allergic to exenatide, investigational drug or any ingredients (citric acid, mannitol, m-cresol); or have specific severe drug allergy history

4. Patient has specific cardiovascular disease, such as unstable angina pectoris, myocardial infarction, hypertension with poor control using one antihypertensive drugs (mean sitting systolic blood pressure = 160mmHg or diastolic blood pressure = 95mmHg), severe arrhythmia, QTc Prolonged, cardiac dysfunction and so on;

5. Subject who has liver and kidney dysfunction (ALT or AST> 2 times of upper limit of normal reference range, or TBIL> 1.5 times of upper limit of normal reference range, or Cr> upper limit of normal reference range);

6. Subject who's triglyceride=5mmol/L;

7. Subject who has acute or chronic hepatitis, or other liver disease

8. Known medical history of acute pancreatitis or chronic pancreatitis, or pancreatic amylase> upper limit of normal reference range, or serum lipase> upper limit of normal reference range;

9. Subject has disease which may impact gastric emptying, such as gastroparesis, gastric outlet obstruction, intestinal obstruction, or received gastric bypass surgery, or long-term use of drugs which may have direct impact on gastrointestinal peristalsis;

10. Subject has any clinical significant major disease history or medical history of respiratory system, digestive system, nervous system, hematology system, urology system, immunology, psychiatric system and metabolic disorders etc.

11. Subject has liver, kidney or gastrointestinal partial resection surgery

12. Subject has drug abuse or alcoholic

13. Subject who has received any Chinese and western medication treatment for diabetes;

14. Subject who has taken any prescription or over-the-counter medications (such as orlistat, sibutramine, rimonabant, phenylpropanol or chlorpheniramine) that promote weight loss within 3 months before study;

15. Take any medications that may affect test results, such as antibiotics, non-steroidal anti-inflammatory drugs, antacids containing aluminum or magnesium, diuretics, anticoagulants, central nervous system inhibitors, systemic corticosteroids, medications to slow down the gastrointestinal motility, and any drug that may possibly affect the absorption of the drug within 2 weeks before screening;

16. Participated any clinical trial within 3 months before trial;

17. Female who is pregnant or lactating;

18. Subject who is not able to use contraceptive methods that is medically recognized during study;

19. Subject who cannot complete study due to other reason or determined by investigators as inappropriate to participate this study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type II Diabetes Mellitus

Intervention

Biological:
• Exenatide injection(Byetta)

• PB-119 injection

Locations

Country	Name	City	State
China	No.1 Hospital of Peking University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
PegBio Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent AE (safety and tolerability)	N of participants with abnormal lab values and AE relevant to the treatment	the change form base line lab values at 3 months
Secondary	PB-119 blood concentration	N of PB-119 blood concentration	hour0, hour12, hour24, hour48, hour72, hour96, hour120, hour144, hour168, hour336, hour504, hour672, hour1344, hour1848, hour1872, hour1896, hour1920, hour2016, hour2112, hour2184 and hour2580